Add on Estradiol to 2% minoxidil offers no additional advantage in Female pattern hair loss, suggests study

For this study, 43 women with FPHL were instructed to apply a spray-on solution comprising either 17α-estradiol 0.01% plus minoxidil 2% (EMX group) or minoxidil 2% alone (MX group) blindfolded twice a day. The course of treatment lasted six months. After baseline and after the conclusion of the therapy, trichoscopic and clinical evaluations were conducted.

Both groups displayed indicators of improvement at the conclusion of the therapy session. The EMX group outperformed the MX group in terms of improvement metrics, however, this difference was not statistically significant. Menstrual abnormalities were more common among the patients of EMX group. Overall, the findings of this study suggest that a 0.01% 17α-estradiol and 2% minoxidil solution does not appear to provide a statistically significant benefit over minoxidil alone, and there may be a greater chance of related menstrual abnormalities in  the treatment of FPHL.

Reference:

Bedair, N. I., EL-Komy, M. H. M., Mohamed, R. E., Shamma, R. N., & Amer, M. A. (2024). Efficacy and safety of combined topical ethinylestradiol with minoxidil versus topical minoxidil in female pattern hair loss. A trichoscopic randomized controlled clinical study. In Clinical and Experimental Dermatology. Oxford University Press (OUP). https://doi.org/10.1093/ced/llae436